(11) Publication number: 0 631 137 A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 94108398.2

(22) Date of filing: 31.05.94

(51) Int. Cl.5: A61B 5/00, G01N 21/35

(30) Priority: 25.06.93 US 83056

(43) Date of publication of application : 28.12.94 Bulletin 94/52

Designated Contracting States :
 DE FR GB IT

(88) Date of deferred publication of search report: 14.06.95 Bulletin 95/24

(1) Applicant: Stark, Edward W. 160 West End Avenue, Suite 3M New York, New York 10023 (US) (2) Inventor: Stark, Edward W. 160 West End Avenue, Suite 3M New York, New York 10023 (US)

(4) Representative: Geyer, Werner et al Patentanwälte Geyer, Fehners & Partner, Perhamerstrasse 31 D-80687 München (DE)

(54) Glucose related measurement method and apparatus.

A method of and apparatus for determining stable and labile glycated compound levels in blood. Electromagnetic energy covering a mulof wavelength bands within a wavelength range from 380 nm to 2500 nm is directed into a sample volume containing blood. Portions of the energy representative of both the source energy and energy after interacting with material within the sample volume are collected. The energy portions carry information relating to the source energy and the levels of labile and stable compounds within the sample volume, respectively. The portions are converted into electrical signals representative of the intensities of the respective portions in each of the multiplicity of wavelength bands. The electrical signals are pretreated in accordance with known information to remove deviations from established reference conditions to form data signals that are a function of the fractional portion of the energy in each of the wavelength bands absorbed and scattered by the material in the measurement volume. Selected groups of the data signals are processed in accordance with chemometric models developed from analysis of such data signals together with known values of the analytes derived from measurements on a calibration set of samples larger in number than the number of wavelength bands included in the set of the selected groups of data signals to develop analyte signals representative of the amounts of glycated compounds for which chemometric models have been developed and utilized. The analyte signals may be stored and displayed in a form suitable for medical use.

MODULATOR 12

MIRRORED OPTICAL
SWITCHING MEANS 13

SOURCE
10
20
21
32
31
23
30
FIG. 2

EP 0 631 137 A3



EUROPEAN SEARCH REPORT

EP 94 10 8398

Category	Citation of document with i of relevant pa	ndication, where appropriate, ssages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CLS)
A	EP-A-0 222 419 (INS 1987 * column 1 - column	T.BIOINGENERIA) 20 May	1,6,11, 17,20,21	A61B5/00 G01N21/35
A,D	US-A-5 204 532 (ROS	ENTHAL) 20 April 1993	1,6,11, 17,20,21	
l	US-A-4 975 581 (ROE COL.9-10;15-17	INSON) 4 December 1990	1,6,11, 17,20,21	
A,D	US-A-5 077 476 (ROS 1991 * column 3 - column	•	1,6,11, 17,20,21	
	APPLIED SPECTROSCOP vol.46, no.10, 1 Oc pages 1575 - 1578 HAALAND ET AL. 'REA DETERMINATION, ETC.'		1,11	TECHNICAL FIELDS
				SEARCHED (Int.Cl.5) GOIN
	The present search report has be	en drawn up for all claims		
	Place of search	Date of completion of the search		Contriber
	THE HAGUE	21 April 1995	Boel	hm, C
X : parti Y : parti docu A : techi	ATEGORY OF CITED DOCUMEN cularly relevant if taken alone cularly relevant if combined with ano ment of the same category nological background written disclosure	E : earlier patent door after the filing da	nment, but publi: te the application	